Incretins, diabetes, and bariatric surgery: a review

Surgery for Obesity and Related Diseases

Volumn 1, Issue 6, 2005, Pages 589-597

  Fetner, Rachel ^a   McGinty, James ^a   Russell, Colleen ^b   Pi Sunyer, F Xavier ^a,b   Laferrère, Blandine ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Bariatric surgery; Gastric inhibitory polypeptide; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin; Obesity; Type 2 diabetes mellitus

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE;

BARIATRIC SURGERY; CLINICAL TRIAL; COMORBIDITY; DIABETES CONTROL; DRUG DOSE REGIMEN; DRUG HALF LIFE; HORMONE DEFICIENCY; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; LONG TERM CARE; META ANALYSIS; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; WEIGHT REDUCTION;

BARIATRIC SURGERY; BILIOPANCREATIC DIVERSION; CEREBRAL CORTEX; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROPLASTY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY, MORBID; POSTOPERATIVE PERIOD; SATIETY RESPONSE;

EID: 33646437805     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2005.09.001     Document Type: Review

References (116)

1. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 160 (2000) 898-904
2. Pories W.J., MacDonald Jr. K.G., Morgan E.J., et al. Surgical treatment of obesity and its effect on diabetes. 10-y follow-up. Am J Clin Nutr 55 (1992) 582S-585S
3. Residori L., Garcia-Lorda P., Flancbaum L., Pi-Sunyer F.X., and Laferrère B. Prevalence of co-morbidities in obese patients before bariatric surgery. effect of race. Obes Surg 13 (2003) 333-340
4. Sjostrom C.D., Lissner L., Wedel H., and Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery. the SOS Intervention Study. Obese Res 7 (1999) 477-484
5. Geloneze B., Tambascia M.A., Pareja J.C., Repetto E.M., and Magna L.A. The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res 9 (2001) 763-769
6. Elahi D., McAloon-Dyke M., Fukagawa N.K., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (7-37) in normal and diabetic subjects. Regul Pept 51 (1994) 63-74
7. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301
8. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide in type 2 diabetic patients. J Clin Endocrinol Metab 86 (2001) 3717-3723
9. Lugari R., Dell'Anna C., Ugolotti D., et al. Effect of nutrient ingestion of glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32 (2000) 424-428
10. Creutzfeldt W. The incretin concept today. Diabetologia 16 (1979) 75-85
11. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
12. Vilsboll T., and Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47 (2004) 357-366
13. Holst J.J., and Orskov C. Incretin hormones. an update. Scand J Clin Lab Invest 234 (2001) 75S-85S
14. Pederson R.A. Gastric inhibitory polypeptide. In: Walsh J.H., and Dockray G.J. (Eds). Gut peptides. biochemistry and physiology (1994), Raven Press, New York 217-260
15. Orskov C., Wettergren A., and Holst J.J. Secretion of the incretin hormones glucagon-like peptide 1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31 (1996) 665-670
16. Gault V.A., O'Harte F.P.M., and Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP). anti-diabetic and anti-obesity potential?. Neuropeptides 37 (2003) 253-263
17. Deacon C.F., Nauck M.A., Meier J., Hucking K., and Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85 (2000) 3575-3581
18. Vilsboll T., Agersoe H., Krarup T., and Holst J.J. Similar elimination rates of GLP-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88 (2003) 220-224
19. Nauck M.A. Is glucagon-like peptide 1 an incretin hormone?. Diabetologia 42 (1999) 373-379
20. D'Alessio D.A., Kahn S.E., Leusner C.R., and Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93 (1994) 2263-2266
21. Vahl T.P., Paty B.W., Fuller B.D., Prigeon R.L., and D'Alessio D.A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37)NH2, and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88 (2003) 1772-1779
22. Vilsboll T., Krarup T., Madsbad S., and Holst J.J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114 (2003) 115-121
23. Flint A., Rabin A., Ersboll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide 1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25 (2001) 781-792
24. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J.J. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38 (1993) 665-673
25. Wettergren A., Wojdemann M., and Holst J.J. Glucagon-like peptide 1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275 (1998) G984-G992
26. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002) 531-544
27. Nauck M.A., and Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 128 (2005) 135-148
28. Flint A., Raben A., Astrup A., and Holst J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
29. Gutzwiller J., Goke B., Drew J., et al. Glucagon-like peptide 1. a potent regulator of food intake in humans. Gut 44 (1999) 81-86
30. Naslund E., Barkeling B., King N., et al. Energy intake and appetite are suppressed by glucagon-like peptide 1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
31. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
32. Turton M., O'Shea D., Gunn I., et al. A role of glucagon-like peptide 1 in the central regulation of feeding. Nature 379 (1996) 69-72
33. Yip R.G., and Wolfe M.M. GIP biology and fat metabolism. Life Sci 66 (2000) 91-103
34. Ebert R., and Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 3 (1987) 1-26
35. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
36. Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus. a concise review, with emphasis on studies in humans. Regul Pept 128 (2005) 149-157
37. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
38. Verdich C., Toubro S., Buemann B., Lysgard M.J., Juul Holst J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety. effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25 (2001) 1206-1214
39. Nauck M.A., Kleine N., Orskov C., et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
40. Preitner E., Ibberson M., Franklin I., et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113 (2004) 635-645
41. Pederson R.A., Satkunarajah M., McIntosh C.H., et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47 (1998) 1046-1052
42. Pamir N., Lynn F.C., Buchan A.M., et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 282; (2003) E931-E939
43. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes. a parallel-group study. Lancet 359 (2002) 824-830
44. Nauck M.A., Holst J.J., and Willms B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29 (1997) 411-416
45. Qualmann C., Nauck M.A., Holst J.J., Orskov C., and Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide 1 (GLP-1) (7-36 amide) in the fasting state in healthy subjects. Acta Diabetol 32 (1995) 13-16
46. Holst J.J. Glucagon-like peptide 1. a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 6 (1999) 1005-1017
47. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans. comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
48. Edwards M.B., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Endocrinol Metab 281 (2001) E155-E161
49. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
50. Agerso H., Jensen L.B., Elbrond B., Rolan P., and Zdravkovis M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002) 195-202
51. Juhl C.B., Hollingdal M., Sturis J., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51 (2002) 424-429
52. Ahren B., Simonsson E., Karssib H., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
53. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
54. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
55. Turner R.C., and Holman R.R. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract 28 (1995) S151-S157
56. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery. a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
57. Kalfarentzos F., Parabolas S., Scrubs G., Khakis I., Looked A., and Mead N. Prospective evaluation of biliopancreatic diversion with Roux-en-Y gastric bypass in the super obese. J Gastrointestinal Surg 8 (2004) 479-488
58. Naslund E., Backman L., Holst J.J., Theodorsson E., and Hellstrom P.M. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8 (1998) 253-260
59. Sarson D.L., Scopinaro N., and Bloom S.R. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5 (1981) 471-480
60. Lauritsen K.B., Christensen K.C., and Stokholm K.H. Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand J Gastroenterol 15 (1980) 489-495
61. Rubino F., Gagner M., Gentileschi P., et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240 (2004) 236-242
62. Buchwald H. Overview of bariatric surgery. J Am Coll Surg 194 (2002) 367-375
63. Gonzalez R., Nelson L.G., Gallagher S.F., and Moor M.M. Anastomatic leaks after laparoscopic gastric bypass. Obes Surg 12 (2004) 1299-1307
64. Profumo R.J. Bariatric surgery. review of common procedures and mortality analyses. J Insur Med 36 (2004) 187-193
65. Kremen A.J., Linner J.H., and Nelson C.H. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg 140 (1954) 439-448
66. Marceau P., Biron S., Bourque R.A., et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg 3 (1993) 29-35
67. Herron D.M. The surgical management of severe obesity. Mt Sinai J Med 71 (2004) 63-71
68. Fobi M.A. Surgical treatment of obesity. a review. J Natl Med Assoc 96 (2004) 61-75
69. Griffen Jr. W.O., Bivins B.A., and Bell R.M. The decline and fall of the jejunoileal bypass. Surg Gynecol Obstetr 157 (1983) 301-308
70. Scopinaro N., Gianetta E., Civalleri D., Bonalumi U., and Bachi V. Bilio-pancreatic bypass for obesity II. initial experience in man. Br J Surg 66 (1979) 618-620
71. Greenway S.E., Greenway III F.L., and Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 137 (2002) 1109-1117
72. Mason E.E., and Ito C.C. Gastric bypass in obesity. Surg Clin North Am 47 (1967) 1345-1354
73. Snow V., Barry P., Fitterman N., Qaseem A., and Weiss K. Pharmacological and surgical management of obesity in primary care. a clinical practice guideline from the ACP. Ann Intern Med 142 (2005) 525-532
74. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis. surgical treatment of obesity. Ann Intern Med 142 (2005) 547-559
75. Fernandez Jr. A.Z., Demaria E.J., Tichansky D.S., et al. Multivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesity. Ann Surg 239 (2004) 698-702
76. Mason E.E. Vertical banded gastroplasty for obesity. Arch Surg 117 (1982) 701-706
77. Brolin R.E. Bariatric surgery and long-term control of morbid obesity. JAMA 288 (2002) 2793-2796
78. Fielding G.A., and Ran C.J. Laparoscopic adjustable gastric band. Surg Clin North Am (2005) 129-140
79. Kuzmak L.I. Gastric banding. In: Dietel M. (Ed). Surgery for the morbidly obese patient (1989), Lea & Febiger, Philadelphia 225
80. Peterli R., Donadini A., Peters T., Ackermann C., and Tondelli P. Re-operations following laparoscopic adjustable gastric banding. Obes Surg 12 (2002) 851-856
81. Kuzmak L.I. Silicone gastric banding. a single and effective operation for morbid obesity. Contemp Surg 28 (1986) 13-18
82. Cottam D.R., Nguyen N.T., Eid G.M., and Schauer P.R. The impact of laparoscopy on bariatric surgery. Surg Endosc 19 (2005) 621-627
83. Xu Y., Ohinata K., Meguid M.M., et al. Gastric bypass model in the obese rat to study metabolic mechanisms of weight loss. J Surg Res 107 (2002) 56-63
84. Rubino F., and Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes. a new perspective for an old disease. Ann Surg 239 (2004) 1-11
85. Pories W.J., Caro J.F., Flicking E.G., Meelheum H.D., and Swanson M.S. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass. Ann Surg 206 (1987) 316-323
86. Pories W.J., Swanson M.S., MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222 (1995) 339-350
87. MacDonald Jr. K.G., Long S.D., Swanson M.S., et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1 (1997) 213-220
88. Hickey M.S., Pories W.J., MacDonald K.G., et al. A new paradigm for type 2 diabetes mellitus. could it be a disease of the foregut?. Ann Surg 55 (1998) 1025-1034
89. Castagneto M., De Gaetano A., Mingrone G., et al. Normalization of insulin sensitivity in the obese patient after stable weight reduction with biliopancreatic diversion. Obes Surg 4 (1994) 161-168
90. Burstein R., Epstein Y., Charuzi I., Suessholz A., Karnieli E., and Shapiro Y. Glucose utilization in morbidly obese subjects before and after weight loss by gastric bypass operation. Int J Obes Relat Metab Disord 19 (1995) 558-561
91. Adami G.F., Cordera R., Marinari G., Lamerini G., Andraghetti G., and Scopinaro N. Plasma ghrelin concentration in the short-term following biliopancreatic diversion. Obes Surg 13 (2003) 889-892
92. Polyzogopoulou E.V., Kalfarentzos F., Vagenakis A.G., and Alexandrides T.K. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 52 (2003) 1098-1103
93. Hughes T.A., Gwynne J.T., Switzer B.R., Herbst C., and White G. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 77 (1984) 7-17
94. Sirinek K.R., O'Dorisio T.M., Hill D., and McFee A.S. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 100 (1986) 781-787
95. Barry R.E., Barisch J., Bray G.A., Sperling M.A., Morin R.J., and Benfield J. Intestinal adaptation after jejunoileal bypass in man. Am J Clin Nutr 30 (1977) 32-42
96. Morinigo R., Casamitjana R., Moize V., Gomis R., and Vidal J. Determinants and relevance of GLP-1 secretion changes following gastric bypass in morbidly obese patients. Int J Obes T3 (2003) P3-P046 S87
97. Jorde R., Burhol P.G., and Johnson J.A. The effect of jejunoileal bypass on postprandial release of plasma gastric inhibitory polypeptide (GIP). Scand J Gastroenterol 16 (1981) 313-319
98. Kellum J.M., Kuemmerle J.F., O'Dorisio T.M., et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 211 (1990) 763-770
99. Sarson D.L., Besterman H.S., and Bloom S.R. Radioimmunassay of gastric inhibitory polypeptide and its release in morbid obesity and after jejuno-ileal bypass (proceedings). J Endocrinol 81 (1979) 155P-156P
100. Clements R.H., Gonzalez Q.H., Long C.I., Wittert G., and Laws H.L. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. Am Surg 70 (2004) 1-4
101. Naslund E., Gryback P., Hellstrom P.M., et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21 (1997) 387-392
102. Horowitz M., Collins P., Harding P., and Shearman D. Gastric emptying after gastric bypass. Int J Obes 10 (1986) 117-121
103. Miholic J., Orskov C., Holst J.J., Kotzerke J., and Meyer H.J. Emptying of the gastric substitute, glucagon-like peptide 1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36 (1991) 1361-1370
104. Miholic J., Orskov C., Holst J.J., Kotzerke J., and Pichlmayr R. Postprandial release of glucagon-like peptide 1, pancreatic glucagon, and insulin after esophageal resection. Digestion 54 (1993) 73-78
105. Naito H., Sakaki I., and Matsuno S. Surgical aspect of enteroinsular axis after gastrointestinal surgery with reference to incretin secretion. Pancreas 16 (1998) 370-378
106. Schirra J., Katschinski M., Weidman C., et al. Gastric emptying and the release of glucagon-like peptide 1, pancreatic glucagon, and insulin after esophageal resection. Digestion 54 (1993) 73-78
107. Vecht J., Masclee A.A., and Lamers C.B. The dumping syndrome. current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol 223 (1997) 21-27
108. Katsuki A., Urakawa H., Gabazza E.C., et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 151 (2004) 573-577
109. Poykko S.M., Kellokosi E., Horkko S., Kaumma H., Kesaniemi Y.A., and Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52 (2003) 2546-2553
110. Anderwald C., Brabant G., Bernoider E., et al. Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 52 (2003) 1792-1798
111. Geloneze B., Tambascia M.A., Pilla V.F., Geloneze S.R., Repetto E.M., and Pareja J.C. Ghrelin, a gut-brain hormone. effect of gastric bypass surgery. Obes Surg 13 (2003) 17-22
112. Dhillo W.S., and Bloom S.R. Gastrointestinal hormones and regulation of food intake. Horm Metab Res 36 (2004) 846-851
113. Korner J., Bessler M., Cirilo L.J., et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90 (2005) 359-365
114. Renshaw D., and Batterham R.I. Peptide YY. a potential therapy for obesity. Curr Drug Targets 6 (2005) 171-179
115. Wettergren A., Wodjeman M., Meisner S., Stadil F., and Holst J.J. The inhibitory effect of glucagon-like peptide 1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40 (1997) 597-600
116. Wettergren A., Petersen H., Orskov C., Christiansen J., Sheikh S.P., and Holst J.J. Glucagon-like peptide 1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29 (1994) 501-505